Retatrutide (LY3437943) has become one of the most studied synthetic peptides in current metabolic research. As a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, it offers researchers a tool for investigating multi-pathway metabolic signaling that single or dual agonists cannot replicate.
This overview covers retatrutide’s structure, mechanism of action, published clinical trial data, handling requirements, and what to look for when sourcing research-grade material.
For research use only. Not for human or animal consumption. Not an FDA-approved therapeutic.
What Is Retatrutide?
Retatrutide is a 39-amino acid synthetic peptide derived from the GIP peptide backbone. It was developed by Eli Lilly under the designation LY3437943 and is currently in Phase 3 clinical trials for obesity and type 2 diabetes — it has not been approved by the FDA for any therapeutic use.
What makes retatrutide structurally distinct is its incorporation of non-standard residues — specifically alpha-aminoisobutyric acid (Aib) substitutions at positions 2 and 20 — which enhance conformational stability and resistance to enzymatic degradation. A C20 fatty diacid chain is conjugated to the peptide to enable albumin binding and extend half-life in experimental systems.
For researchers, this structural complexity means retatrutide behaves differently from simpler peptides in terms of solubility, stability, and storage requirements — all factors worth accounting for before beginning an experiment.
Mechanism of Action: Triple Receptor Agonism
Most incretin-based research compounds target one receptor. Retatrutide targets three:
GIP Receptor (GIPR): Retatrutide shows the highest binding affinity at the GIPR. GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone that potentiates insulin secretion in response to nutrient intake. GIPR activation also plays a role in lipid metabolism and adipose tissue signaling — pathways of significant research interest.
GLP-1 Receptor (GLP-1R): GLP-1 receptor agonism drives insulin secretion, suppresses glucagon release, and slows gastric emptying. This is the mechanism shared with semaglutide and other well-studied GLP-1 agonists, making retatrutide a useful comparative compound in receptor-signaling studies.
Glucagon Receptor (GCGR): The glucagon receptor component is what separates retatrutide from dual agonists like tirzepatide. GCGR activation increases hepatic glucose output and energy expenditure — effects that, in combination with GLP-1R and GIPR agonism, create a layered metabolic signaling profile that researchers are actively characterizing.
The simultaneous activation of all three pathways makes retatrutide a valuable probe for studying how coordinated incretin and glucagon signaling interacts in metabolic regulation — something that cannot be replicated by using individual agonists in combination.
Published Clinical Trial Data
Retatrutide has been studied in two major published trials relevant to researchers building preclinical models:
Phase 2 Obesity Trial (NEJM, 2023): A randomized, double-blind, placebo-controlled trial in adults with BMI ≥30. Participants receiving the highest dose showed substantial reductions in body weight over 48 weeks. The trial established dose-response relationships and characterized the safety profile at multiple dose levels — data that informs preclinical dosing model design.
Phase 2 Type 2 Diabetes Trial (The Lancet, 2023): Evaluated retatrutide’s effect on glycemic control in adults with type 2 diabetes. Results demonstrated meaningful reductions in HbA1c alongside body weight changes, establishing retatrutide’s dual metabolic profile as a research subject.
Phase 3 trials are currently underway across multiple indications including obesity, type 2 diabetes, obstructive sleep apnea, cardiovascular outcomes, and metabolic-associated steatotic liver disease (MASLD). Published Phase 3 data will significantly expand the research landscape for this compound.
Handling, Storage, and Reconstitution
Proper handling is critical for maintaining retatrutide’s structural integrity in research applications.
Storage — Lyophilized (Powder): Store at -20°C in a dry environment. Properly stored lyophilized retatrutide maintains stability for up to 24 months. Avoid repeated temperature cycling during storage.
Reconstitution: Retatrutide is soluble in bacteriostatic water or sterile water. Add solvent slowly along the vial wall — do not vortex or shake aggressively, as mechanical disruption can compromise the peptide’s structural integrity. Allow the solution to dissolve at room temperature or with gentle rotation.
Storage — Reconstituted: Store at 4°C (refrigerated) and use within 4 weeks. Avoid freeze-thaw cycles on reconstituted solution. Label vials with reconstitution date.
Working concentration: Prepare at the concentration required for your specific assay. Because retatrutide engages multiple receptor pathways, pilot experiments at varying concentrations are advisable before committing to a full experimental run.
What to Look For When Sourcing Research-Grade Retatrutide
Sourcing quality matters more for a structurally complex peptide like retatrutide than for simpler compounds. The Aib substitutions and fatty acid conjugation that make it useful in research also make it harder to synthesize correctly — meaning low-quality synthesis can produce material that behaves inconsistently in assays.
When evaluating a supplier, look for:
HPLC purity report: Should show ≥98% purity. The chromatogram should be included — a purity number without the underlying data is not verifiable.
Mass spectrometry confirmation: HPLC confirms purity but not identity. Mass spec confirms the peptide is actually retatrutide (correct molecular weight: ~4,858 Da) and not a similar compound or impurity masquerading as the target peptide.
Endotoxin testing: Relevant for any cell-based or in vivo model work. Endotoxin contamination introduces confounding variables that are difficult to distinguish from peptide-specific effects.
Lot-specific COA: A certificate of analysis should be specific to the batch you’re receiving — not a generic document reused across lots. Each synthesis run can vary, and lot-specific data is the only way to verify consistency.
At Peptiva, every batch of retatrutide is independently verified by Mazbiolabs with HPLC and mass spectrometry. Lot-specific COAs are published on our COA page and included with every order.
Frequently Asked Questions
Is retatrutide FDA-approved? No. Retatrutide is currently in Phase 3 clinical trials and has not received FDA approval for any therapeutic indication. Research-grade retatrutide is available strictly for laboratory and in vitro research use.
What is the molecular weight of retatrutide? Retatrutide has a molecular weight of approximately 4,858 Da. Mass spectrometry confirmation of this value is one way to verify peptide identity in a COA.
How does retatrutide differ from tirzepatide? Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide adds glucagon receptor (GCGR) agonism as a third target, enabling research into how glucagon signaling interacts with incretin pathways — a dimension not accessible with tirzepatide.
What solvent is used for reconstitution? Bacteriostatic water is the standard solvent for retatrutide reconstitution. Sterile water can be used for single-use applications. Avoid acidic solvents.
What sizes does Peptiva offer? We carry retatrutide in 5mg, 10mg, 15mg, and 30mg formats. View current availability →
All products are for research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease.
